<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03283384</url>
  </required_header>
  <id_info>
    <org_study_id>BOOG-2017-01</org_study_id>
    <secondary_id>2017-000676-29</secondary_id>
    <nct_id>NCT03283384</nct_id>
  </id_info>
  <brief_title>Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.</brief_title>
  <acronym>NEOLBC</acronym>
  <official_title>Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Borstkanker Onderzoek Groep</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, randomized, multicenter, open-label, phase II study is to test
      if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a
      neo-adjuvant therapy for patients with non-metastatic primary luminal breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on Ki67 levels after two weeks of initial letrozole treatment in postmenopausal
      patients with hormone receptor positive, HER2 negative, stage II/III breast cancer, patients
      are either advised to continue letrozole treatment (if Ki67 &lt;1%) or will be randomized
      between standard chemotherapy (AC-T) or ribociclib in combination with letrozole (if Ki67
      ≥1%).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in complete cell cycle arrest (CCCA; defined as Ki67 IHC &lt;1%) between ribociclib plus letrozole and chemotherapy in the surgical specimen.</measure>
    <time_frame>CCCA will be determined in the surgical specimen, which is around 7 months after start of initial letrozole treatment.</time_frame>
    <description>Determine if ribociclib plus letrozole gives a &gt;50% improvement in CCCA as compared to chemotherapy in the surgical specimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between Ki67 IHC scored manually, IHC scored automatically (Vectra ® 3) and Ki67 mRNA.</measure>
    <time_frame>Ki67 measurements will be done in the primary core biopsy (baseline), two weeks biopsy (done after two weeks of initial letrozole treatment) and the surgical specimen (which is around 7 months after start of initial letrozole treatment).</time_frame>
    <description>The correlation between the different Ki67 measurements will be determined in the primary core biopsy, two weeks biopsy and surgical specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between ER pathway activity at baseline, after two weeks letrozole and at surgery and clinical outcome.</measure>
    <time_frame>ER pathway activity will measured in the primary core biopsy (baseline), two weeks biopsy (done after two weeks of initial letrozole treatment) and the surgical specimen (which is around 7 months after start of initial letrozole treatment).</time_frame>
    <description>The ER pathway activity will be determined in the primary core biopsy, two weeks biopsy and surgical specimen and then correlated with clinical outcome.
Activity will be determined using a Bayesian network model of the ER transcriptional program, which interprets the pathway target genes' mRNA levels (from Affymetrix HG-U133Plus2.0 arrays) and infers a probability that the ER pathway is active in a certain sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in pathologic response (pCR and response according to Miller and Payne) between the randomized study arms.</measure>
    <time_frame>pCR and response according to Miller and Payne will be determined in the surgical specimen, which is around 7 months after start of initial letrozole treatment.</time_frame>
    <description>The pathologic response will be determined in the surgical specimen of the patients in the randomized study arms where after the difference between the two groups can be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor biology and biomarkers (ER, PR, HER2, Rb, Ki67) at baseline, after 2 weeks letrozole and at surgery.</measure>
    <time_frame>Tumor biology and biomarkers will be assessed in the primary core biopsy (baseline), two weeks biopsy (done after two weeks of initial letrozole treatment) and the surgical specimen (which is around 7 months after start of initial letrozole treatment).</time_frame>
    <description>Tumor biology and biomarkers will be determined in the primary core biopsy, two weeks biopsy and surgical specimen, where after the change in tumor biology and biomarkers over time can be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI CTCAE v4.03 all grades and grade III/IV.</measure>
    <time_frame>Toxicity will be assessed from start treatment up to 30 days following the last dose of treatment.</time_frame>
    <description>Toxicities are graded according to NCI CTCAE v4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of tumor measurements between standard MRI (using RECIST 1.1) and palpation (largest diameter in cm) at baseline, after 12 weeks of therapy and pre-surgery.</measure>
    <time_frame>Tumor measurements (MRI and palpation) will be performed at baseline, after 12 weeks of therapy and pre-surgery (which is around 7 months after start of initial letrozole treatment).</time_frame>
    <description>The correlation of tumor measurements between MRI and palpation will be determined at three different time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of event free survival (EFS) at 3 and 5 years.</measure>
    <time_frame>EFS will be determined after 3 and 5 years.</time_frame>
    <description>EFS is defined as the time from randomization to the first date of local, regional, or distant relapse, second primary invasive breast cancer including contralateral breast cancer, progression according to RECIST 1.1 or death due to any cause which ever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of overall survival (OS) at 3 and 5 years.</measure>
    <time_frame>Time Frame: OS will be determined after 3 and 5 years.</time_frame>
    <description>OS is defined as the time from randomization to date of death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in ERα DNA binding signatures (Chip-seq) between baseline and after 2 weeks letrozole.</measure>
    <time_frame>ERα DNA binding signatures will be assessed in the primary core biopsy (baseline) and the two weeks biopsy (done after two weeks of initial letrozole treatment).</time_frame>
    <description>ERα DNA binding will be determined in the primary core biopsy and two weeks biopsy, where after the change in these measurements over time can be determined.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in gene expression profiles (RNA-seq) between baseline and after 2 weeks letrozole.</measure>
    <time_frame>Gene expression profiles will be assessed in the primary core biopsy (baseline) and the two weeks biopsy (done after two weeks of initial letrozole treatment).</time_frame>
    <description>Gene expression profiling will be determined in the primary core biopsy and two weeks biopsy, where after the change in these measurements over time can be determined.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Advise letrozole, treatment choice free.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of &lt;1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribociclib plus letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 2.5 mg daily.</description>
    <arm_group_label>Advise letrozole, treatment choice free.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>AC-T chemotherapy: 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 3-weekly, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m² weekly).</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib plus letrozole</intervention_name>
    <description>Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).</description>
    <arm_group_label>Ribociclib plus letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women presenting with histological proven (core biopsy material)
             hormone receptor positive (ER&gt;50%, PR any), HER2 negative, stage II/ III breast
             cancer.

          -  Measurable disease (breast and/or lymph nodes)

          -  WHO 0-2

          -  Adequate bone marrow function (within 4 weeks prior to registration): WBC≥3.0x109/l,
             neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l

          -  Adequate liver function (within 4 weeks prior to registration): bilirubin ≤1.5 x upper
             limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x
             UNL

          -  Adequate renal function (within 4 weeks prior to registration): the calculated
             creatinine clearance should be ≥50 ml/min

          -  Accessible for treatment and follow-up

          -  Written informed consent

        Inclusion criteria randomization specific:

        In order to be eligible to be randomized in this study, a subject must meet all of the
        following criteria:

          -  Registration in the NEOLBC trial before start of letrozole

          -  Use of letrozole

          -  Outcome central Ki67 determination in two weeks biopsy available.

        Exclusion Criteria:

          -  Evidence of distant metastases (M1)

          -  Previous invasive breast cancer

          -  Prior chemotherapy, hormonal therapy or radiation therapy

          -  Previous malignancy within 5 years, with exception of a history of a previous basal
             cell carcinoma of the skin or pre-invasive carcinoma of the cervix.

          -  Peripheral neuropathy &gt; grade 2, whatever the cause

          -  Serious other diseases as infections (hepatitis B, C and HIV), recent myocardial
             infarction, clinical signs of cardiac failure or clinically significant arrhythmias or
             on screening, any of the following cardiac parameters: bradycardia (heart rate &lt;50 at
             rest), tachycardia (heart rate &gt; 90 at rest), PR interval &gt; 220 msec, QRS interval
             &gt;109 msec, or QTcF &gt;450 msec.

          -  Known hypersensitivity reaction to any of the components of the treatment

          -  Currently receiving warfarin or other coumarin derived anti-coagulant, for treatment,
             prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH),
             or fondaparinux is allowed.

          -  Currently receiving any of the following substances and cannot be discontinued 7 days
             prior to randomisation:

               -  Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit
                  hybrids, pummelo's, star-fruit, and Seville oranges.

               -  That have a known risk to prolong the QT interval or induce Torsades de Pointes.

               -  That have a narrow therapeutic window and are predominantly metabolized through
                  CYP3A4/5.

               -  Herbal preparations/medications, dietary supplements.

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or sign meaningful informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith R Kroep, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabine C Linn, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerrit-Jan Liefers, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith R Kroep, MD PhD</last_name>
    <phone>+31715263464</phone>
    <email>j.r.kroep@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A F de Groot, MD</last_name>
    <phone>+31715261032</phone>
    <email>a.f.de_groot@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. Tol</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente (Twenteborg ZH Almelo)</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Siemerink</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Amstelland</name>
      <address>
        <city>Amstelveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. van Zweeden</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut - Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S. Linn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis (Oost)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. Meerum Terwogt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stichting Reinier Haga Groep (Reinier de Graaf Gasthuis)</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K. Beelen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stichting Deventer Ziekenhuisgroep Rielerenk</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L. Kessels</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B. Vriens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum (Eindhoven)</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. Dercksen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis (Bleuland)</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. Hokken</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis (Haarlem-Zuid)</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>P. Kuijer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis St. Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. Ropela</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen (Hilversum)</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S. Luykx-de Bakker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westfriesgasthuis</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S. van den Heiligenberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith R Kroep, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. de Boer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C. Mandigers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bravis Ziekenhuis (Roosendaal)</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H. Droogendijk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis Sneek</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>G. Veldhuis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Rivierenland</name>
      <address>
        <city>Tiel</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C. Kruijtzer-Schimmel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum (Venlo)</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. van de Wouw</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Streekziekenhuis Koningin Beatrix</name>
      <address>
        <city>Winterswijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>P. Schiphorst</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala (Zwolle)</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. Honkoop</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.boogstudycenter.nl/studie/286/neolbc.html</url>
    <description>Information NEOLBC study on BOOG website (sponsor).</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Ribociclib</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <keyword>Ki67</keyword>
  <keyword>NEOLBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

